Drug Candidates for the Treatment of Atopic Dermatitis
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: closed (25 January 2025) | Viewed by 3142
Special Issue Editor
Special Issue Information
Dear Colleagues,
Atopic dermatitis (AD) is an immune-mediated skin disease influenced by immune system imbalance, genetic defects, and environmental conditions. It has been studied as the most common inflammatory skin disease, with a worldwide prevalence ranging from 1 to 3% in adults and 5 to 10% in children. It is especially true that the incidence of AD has been gradually increasing globally due to changes in lifestyle. Therefore, the discovery of therapeutics or compounds that attenuate the symptoms of AD is increasingly necessary.
Several strategies to conquer AD have been widely used. Since dry environments surrounding the skin barrier exacerbate AD manifestations, the treatment of AD focuses on how to maintain the moisture content of the skin barrier. Although steroids are also widely used for attenuating AD symptoms over a short period of time, a variety of studies have demonstrated severe disadvantages of steroid use when administered over a long time. Recent approaches for AD treatment have moved to the identification of potent candidates from naturally derived compounds due to their safety in long-term use and outstanding efficacy. A number of studies have shown that compounds discovered from natural products control the activity of immune cells for people with AD.
This Special Issue aims to collect reviews that consider the current state of the art and future prospects in the field of atopic dermatitis, as well as original research articles reflecting.
Dr. Hyun-Su Lee
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- atopic dermatitis
- skin barrier
- skin disease
- house-dust-mite-induced atopic dermatitis
- small molecules for atopic dermatitis treatment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
